Welcome to our dedicated page for PROCTER & GAMBLE Co SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROCTER & GAMBLE Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROCTER & GAMBLE Co's regulatory disclosures and financial reporting.
Form 144 filed for Procter & Gamble Company (PG). The filer notified intent to sell 15,328 shares of common stock through Morgan Stanley Smith Barney LLC on 08/19/2025, with an aggregate market value of $2,374,383.84. The shares were acquired on 08/18/2025 as a Performance Stock Program Award from The Procter & Gamble Company, totaling 30,815 shares received and showing 2,342,371,488 shares outstanding. The filer reported no sales in the past three months and included the standard representation that they are not aware of undisclosed material adverse information. The notice indicates the transaction will be executed on the NYSE.
Form 144 notice for Procter & Gamble (PG) shows a proposed sale of 376 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $58,244.28 and approximately 2,342,371,488 shares outstanding. The securities were acquired on 08/18/2025 as a Performance Stock Program Award from The Procter & Gamble Company and payment was recorded on 08/18/2025. No securities of the issuer were reported sold by the filer in the past three months. The filer affirms they are not aware of undisclosed material adverse information about the issuer.
Procter & Gamble Company (PG) Form 144 notice: The filer notified intent to sell 10,686 shares of Procter & Gamble common stock through Morgan Stanley Smith Barney on 08/19/2025 on the NYSE. The filing lists an aggregate market value of $1,655,314.83 and reports 2,342,371,488 shares outstanding. The shares to be sold were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company; the acquisition quantity is reported as 22,496 shares with payment on 08/18/2025. The filer attests there is no undisclosed material adverse information and includes the standard signature and criminal-penalty notice applicable to Form 144.
Procter & Gamble (PG) filing a Rule 144 notice shows a proposed sale of company common stock through Morgan Stanley Smith Barney LLC on 08/19/2025. The notice lists two lots: 929 shares with an aggregate market value of $143,906.75 and 12,963 shares with an aggregate market value of $2,008,033.52. The total outstanding shares reported for the issuer are 2,342,371,488, making the proposed sale a vanishingly small fraction of the company’s float.
The securities were acquired on 08/18/2025 as Performance Stock Program awards from The Procter & Gamble Company and payment/consideration is listed as NA. The filer certifies there are no known undisclosed material adverse facts and reports no securities sold by the person in the past three months.
Procter & Gamble (PG) Form 144 notice: The filer reports a proposed sale of 47,232 shares of Procter & Gamble common stock, with an aggregate market value of $7,316,472.96, to be executed through Morgan Stanley Smith Barney LLC on the NYSE on 08/19/2025. The securities were acquired the prior day, 08/18/2025, as a Performance Stock Program Award from The Procter & Gamble Company, totaling 89,360 shares awarded and paid on 08/18/2025.
The filing states there were 2,342,371,488 shares outstanding at the time of the notice and reports no securities sold by the person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Procter & Gamble Form 144 notice reports a proposed sale of 714 shares of common stock, with an aggregate market value of $110,602.17, to be sold on the NYSE on or about 08/19/2025. The shares were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company and were paid for on 08/18/2025. The filing lists total shares outstanding of 2,342,371,488, indicating the sale is immaterial relative to the companys total float. The filer certifies they are unaware of any undisclosed material adverse information and provides standard Rule 144 representations regarding trading plans and compliance.
Form 144 notice for Procter & Gamble Company (PG). The filer notifies intent to sell 11,198 shares of Common Stock through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 08/19/2025. The aggregate market value of the proposed sale is reported as $1,734,626.19 and the issuer's shares outstanding are shown as 2,342,371,488. The securities were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company; the filer lists acquiring 18,834 shares and indicates payment on 08/18/2025. No sales in the past three months are reported. The notice includes the standard representation about lack of undisclosed material adverse information.
Alexandra Keith, Chief Executive Officer – Beauty at The Procter & Gamble Company, has announced her intention to retire effective February 20, 2026, after more than 36 years with the company. Upon retirement she will enter the company’s standard Written Separation Agreement, which does not provide any cash severance and allows her to retain the remainder of a special equity award scheduled to vest in August 2026.
Per the report, all other equity awards will be retained or pro-rated as set out in the applicable Award Agreement. The disclosure does not include details about a successor or additional transition arrangements.
Procter & Gamble (PG) – Form 4 filed 08/07/2025. Chief Operating Officer Shailesh Jejurikar disclosed only acquisitions, no sales of company equity.
- Direct common stock: 9,982.2858 shares after the transactions.
- Indirect common stock: 3,301.9815 shares via retirement plan; 19,757 shares in the Sankhya S Jejurikar Revocable Trust; 17,849 shares in the Shailesh Jejurikar Trust.
- Derivative activity: Four separate grants of Restricted Stock Units (RSUs) and preferred-stock equivalents were reported: 31.0041 RSUs (02/18/25), 33.4003 RSUs (05/15/25), 0.3416 Series A preferred shares convertible into common stock (07/14/25), and 725 RSUs as a retirement award (08/07/25).
- All entries carry transaction code “A” (acquisition), and each grant was made at $0 cost as part of dividend-equivalent, retirement, or compensation programs.
- Total derivative holdings following the filing: 494.5685 + 527.9688 + 1,001.0622 + 725 ≈ 2,749 units/shares, split between direct and retirement-plan accounts.
No dispositions, option exercises, or open-market trades were reported; the filing merely updates ownership records and corrects small prior misstatements related to dividend-equivalent RSUs.